Written by: Jody Agena, PharmD, MBA, BCOP
Ibrutinib (Imbruvica) has indications in Mantle Cell Lymphoma, Chronic/Small Lymphocytic Leukemia, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Graft Versus Host Disease (GVHD). This PQI will discuss strategies for medication dosing and adverse event management to improve patient outcomes.
Continue reading Ibrutinib Management
NCODA is closely watching today’s hearing on the issue of drug pricing. We will see the CEOs from AbbVie, AstraZeneca, Bristol-Myers Squibb, Merck & Co, Pfizer, and Sanofi (plus the head of J&J’s pharma division) debate drug prices with lawmakers at a time when major legislative reform seems to be looming. More
Women & Infants Hospital, a teaching hospital of The Warren Alpert Medical School of Brown University, is committed to improving the health and well-being of women and infants and to providing our essential services regardless of ability to pay. Continue reading Women & Infants Hospital (Rhode Island)
NCODA supports the principle that medications should improve the patient’s quality of life while simultaneously treating the disease. We will continue to follow these developments as our patient-centered approach reaches the heart of clinical trial design in the oncology space. Article here
Former NCODA Keynote Speaker Doug Collins (R-Ga.) reintroduced legislation that would increase transparency in drug pricing while lowering costs for patients. Updates on H.R. 1035 The Prescription Drug Pricing Transparency Act and H.R. 1034 The Phair Pricing Act can be found here at NCODA as we continue to advocate for cancer patients. Read More